Amphastar Pharmaceuticals Stock News

Amphastar stock has generated high rates of post-tax earnings growth with small increments of additional capital investment since FY20. The incremental returns on capital are above historical returns

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Cl

Quarter-over-Quarter growth in revenue has persisted due to the consistent launch of new product pipelines. The overall financial position is substantially strong, which offers significant flexibility

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Ch

Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2

Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.

Amphastar's profitability and cash flow have been increasing consistently, and with management's efforts, profitability will increase significantly. Having a solid financial position and consistent gr

Back in August, I made the argument why now's the right time to buy safe stocks. Just over a month later, this continues to be the case.

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sale

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2022 Results Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Pete

Amphastar (AMPH) delivered earnings and revenue surprises of 5.41% and 4.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amphastar and Syndax, two top-rated biotech stocks, topped second-quarter estimates on Tuesday. But shares stayed flat.

Amphastar currently has seven drugs under development, two drugs awaiting launch, and a base of over nine FDA-approved products in production. With the recent approval of generic ganirelix and vasopre